Authors
Latest:
Advancing the Treatment Landscape in Philadelphia-Positive ALLKey opinion leaders review the evolution of Ph+ ALL treatment, from Hyper-CVAD to novel TKIs, blinatumomab, and deintensification, improving remission rates and survival.
Latest:
The Potential Future Impact of CAR T Cell Therapy in Adult ALLExperts in hematology oncology consider unmet needs for adult patients with relapsed/refractory ALL and reflect on the potential impact that FDA approval of CAR T cell therapy would have on the treatment landscape.
Latest:
Dr. Piperdi Discusses RICTOR Amplification in Lung CancerBilal Piperdi, MD, discusses an analysis presented at the 2014 ASCO Annual Meeting that looked at RICTOR amplification to define a subset of patients with lung cancer.
Latest:
Bin Zheng on the Potential of Diabetes Drugs in MelanomaBin Zheng, PhD, assistant professor of Dermatology at Harvard Medical School and assistant biologist at Massachusetts General Hospital, discusses the potential for phenformin, a drug created for Type 2 diabetes, to be used for patients with melanoma.
Latest:
Dr. Xia on the Frontline Treatment Landscape of ALK-Positive NSCLCBing Xia, MD, assistant professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses the frontline treatment landscape of ALK-positive non–small cell lung cancer (NSCLC).
Latest:
Dr Dhakal on Notable Multiple Myeloma Trials Presented in 2024Binod Dhakal, MD, discusses key trials presented at the 21st International Myeloma Society Annual Meeting in patients with multiple myeloma.
Latest:
Age Cutoff for Pap Tests QuestionedMore than 12% of newly diagnosed cervical cancers occurred in women aged 70 to 85 years during 2000 to 2006
Latest:
Dr. Wistinghausen on Developing Drugs for Children With CancerBirte Wistinghausen, MD, medical director of the Division of Pediatric Hematology-Oncology, the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai, discusses developing drugs for children with cancer.
Latest:
Looking Ahead: Novel Therapies and Future Perspectives in the Treatment of CLLThe panel concludes its discussion with a look to the future of CLL treatment, focusing on emerging novel agents and exciting clinical research.
Latest:
Camidge and Rimel on the Importance of Cultivating Inclusive Gynecologic Oncology PracticesDrs Camidge and Rimel spotlight Dr Rimel’s career journey and the work she does to expand medical care for transgender patients.
Latest:
Bob Asinof on Recruiting Physicians to Private CentersBob Asinof, chief executive officer of The Urology Center of Colorado, discusses the challenges of recruiting urologists to their center while competing with larger cancer centers and hospital systems.
Latest:
Managing the Growth of NCODABob Orzechowski, MBA, Lancaster Cancer Center, discusses managing the growth of NCODA.
Latest:
Dr. Li on the Limitations of the IMpower010 Trial in Resected Stage IB-IIIA NSCLCBob T. Li, MD, PhD, MPH, discusses the limitations of the phase 3 IMpower010 trial in resected stage IB to IIIA non–small cell lung cancer.
Latest:
Advantages of Off-the-Shelf CAR NK Therapy in B-Cell MalignanciesBob Valamehr, PhD, chief development officer at Fate Therapeutics, discusses the advantages of off-the-shelf CAR NK therapy in B-cell malignancies.
Latest:
Dr. Rimel on the Importance of BRCA and HRD Testing in Ovarian CancerBobbie J. Rimel, MD, discusses the importance of testing patients with ovarian cancer for homologous recombination deficiency (HRD) or homologous recombination proficiency (HRP), and BRCA mutation status.
Latest:
The Case for Platinum Therapy in Prostate CancerThe arsenal of therapeutic options for men with castration-resistant prostate cancer has steadily grown as ongoing research uncovers more about prostate cancer biology and resistance mechanisms.
Latest:
Bonnie Addario on Lung Cancer Support GroupsBonnie Addario, a lung cancer survivor and founder of the Bonnie J. Addario Lung Cancer Foundation (BJALCF), discusses support groups for patients with lung cancer.
Latest:
Sequencing Chemo After Radium-223 Safe in mCRPCDetermining the optimal sequencing of novel agents with standard chemotherapy has become a key issue in the management of castration-resistant prostate cancer.
Latest:
Addition of Vorinostat to Bortezomib Achieves Modest Improvement in Progression-Free Survival in Relapsed/Refractory Multiple MyelomaVorinostat added to bortezomib improved progression-free survival compared with bortezomib plus placebo in patients with relapsed/refractory multiple myeloma.
Latest:
Dr Kahl on Ongoing and Planned Investigations Within the Landscape of MCLBrad S. Kahl, MD, discusses ongoing and planned investigations within the landscape of mantle cell lymphoma.
Latest:
Dr Kahl on the Potential for Frontline BTK Inhibitors in Mantle Cell LymphomaBrad S. Kahl, MD, discusses the potential for BTK inhibitors to shift the frontline treatment setting in mantle cell lymphoma.
